* Regulus Therapeutics Inc is expected to show no change in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Regulus Therapeutics Inc is for a loss of 17 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Regulus Therapeutics Inc is 7.50, above its last closing price of $1.49.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.16 -0.15 -0.17 Missed -15.9
Mar. 31 2024 -0.26 -0.22 -0.29 Missed -30.3
Dec. 31 2023 -0.40 -0.39 -0.40 Missed -1.3
Sep. 30 2023 -0.41 -0.40 -0.40 Met -0.8
Jun. -0.41 -0.41 -0.37 Beat 9.8
30 2023
Mar. 31 2023 -0.44 -0.44 -0.42 Beat 3.8
Jan. 1 0001 -0.51 -0.40 Beat 21.6
Sep. 30 2022 -0.49 -0.49 -0.50 Missed -2
This summary was machine generated November 6 at 14:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。